Opinion|Videos|April 14, 2025
Role of Rebiopsy at Disease Progression in EGFRm NSCLC
Panelists discuss how second-line therapy after osimertinib monotherapy depends on resistance mechanisms. If MET amplification, consider MET inhibitors plus EGFR tyrosine kinase inhibitors (TKIs). For C797S mutation, potential options include first- or third-generation EGFR TKI combinations. Chemotherapy remains a key fallback.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Regarding treatment sequencing, how do you approach second-line therapy after osimertinib monotherapy?
Advertisement
Related to this article
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Laurence J. DiNardo, MD, FACS, discusses ctDNA testing in head and neck cancers, advancements in targeted therapies, and multidisciplinary collaboration.
Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.
Roswell Park Comprehensive Cancer Center received a grant to advance CAR T-cell therapy research in pediatric AML.
The FDA approved SimpleScreen CRC as a screening option for colorectal cancer in adults 45 years of age and older at average risk for the disease.
Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.
Safusidenib produced a 51.9% confirmed ORR and a 79.1% 36-month PFS rate in chemotherapy- and radiotherapy-naive grade 2 IDH1-mutant glioma.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualizing ARPI-based therapy in advanced prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
4
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
5